MindMed provides updates on two of its research initiatives, in partnership with the Liechti Lab (Switzerland).

Novamind announces that its shares are now eligible for electronic clearing through the DTC.

Small Pharma shows DMT to be well-tolerated and safe for the study population as it moves forward toward a Phase IIa clinical trial.

Mydecine announces filing of patent application for psilocybin-based MYCO-003. Pre-clinical data is showing MYCO-003 to work better than pure psilocybin.

Recent market clues are suggesting that a much overdue rally for psychedelic stocks may be about to begin.

For most of his adult life, Aaron Presley, age 34, felt like a husk of a person, a piece of “garbage.”

A former Republican congresswoman is touting the therapeutic benefits of psychedelics, sharing the story of how a close family friend was able to recover from alcoholism with the help of psilocybin.

No one can stay awake forever. While we’re awake, our need for sleep gradually increases.

A recent study published in the journal Psychopharmacology suggests that users of synthetic cannabinoid products—such as Spice or K2 —experience more severe withdrawal symptoms than cannabis users, according to an International Business Times outline of the research. It is the first study focused on the long-term and withdrawal effects of using synthetic cannabinoids.

Psyched Wellness is preparing for a clinical sleep study for its proprietary extract, AME-1.